Belite Bio BLTE
NASDAQ BLTE
$186.40 +15.31 (+8.95%)
As of: Sep 4, 2026 · 2:29 PM EDT

Belite Bio (BLTE) EV to EBITDA (2022 - 2026)

Analysis

Belite Bio (BLTE) EV to EBITDA (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.78 Bn 130.92 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.50 Bn 77.51 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.06 Bn 52.92 Bn 52.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn -
6 BeOne Medicines 40.04 Bn 34.94 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn -
9 Insmed 27.42 Bn 26.26 Bn 358.27 Mn
10 Belite Bio 6.26 Bn 6.26 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -173.55
Mar 31, 2026 -191.91
Dec 31, 2025 -20.66 Mn
Sep 30, 2025 -95.50
Jun 30, 2025 -104.36
Mar 31, 2025 -135.82
Dec 31, 2024 -16.30 Mn
Sep 30, 2024 -140.30
Jun 30, 2024 -127.17
Mar 31, 2024 -134.30
Dec 31, 2023 -179.07
Sep 30, 2023 -58.05
Jun 30, 2023 -4.15 Mn
Mar 31, 2023 -86.80
Dec 31, 2022 -83.35
Jun 30, 2022 -127.67